Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
Revive Therapeutics (RVV) is partnering with the University of Wisconsin-Madison to conduct two exciting new psilocybin studies.
One study will research the effect of psilocybin on traumatic brain injury (TBI) and strokes, expanding on preclinical findings that psilocybin improved cognitive function in mice with TBI.
Revive will also conduct a Phase 1/2 clinical study to determine psilocybin’s impact on adults with methamphetamine use disorder. Both studies will begin patient enrollment by the end of the year.